John C. Reed
Known title: DirectorCIK: 0001181561
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Johnson & Johnson: Key Takeaways for Long-Term Investors. Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.
Transaction History
| MDGL | ▲ Buy | Grant | 647 | $0 | 8/15/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 25,255 | $0 | 5/1/2026 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 11,002 | $2.5M | 5/1/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 21,721 | $3.4M | 2/17/2026 | View on chart |
| JNJ | ▼ Sell | Open Market | 21,721 | $5.3M | 2/17/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 29,927 | $4.7M | 2/17/2026 | View on chart |
| JNJ | ▼ Sell | Open Market | 29,927 | $7.3M | 2/17/2026 | View on chart |
| JNJ | ▼ Sell | Open Market | 2,283 | $555K | 2/17/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,349 | $0 | 2/15/2026 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 385 | $94K | 2/15/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,847 | $0 | 2/15/2026 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 528 | $129K | 2/15/2026 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 21,721 | $3.4M | 10/17/2025 | View on chart |
| JNJ | ▼ Sell | Open Market | 21,721 | $4.2M | 10/17/2025 | View on chart |
| JNJ | ▼ Sell | Open Market | 19,137 | $3.1M | 7/17/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 25,255 | $0 | 5/1/2025 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 11,002 | $1.7M | 5/1/2025 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 385 | $60K | 2/18/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 1,350 | $0 | 2/15/2025 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 22,255 | $0 | 5/1/2024 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 10,984 | $1.6M | 5/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data
Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data. Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.